PubRank

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Clinical Trial ID NCT01352884

PubWeight™ 24.68‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01352884

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
2 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
3 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
4 Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012 1.71
5 Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 2013 1.59
6 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
7 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
8 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
9 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
10 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
11 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
12 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
13 Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. Biomed Res Int 2015 0.83
14 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
15 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
16 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
17 Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discov Today 2015 0.78
18 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
19 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
Next 100